Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Endocrinology | Family Medicine | Geriatrics | Gynecology | Internal Medicine | Nursing | Orthopedics | Radiology | Rheumatology | Conference News

Back to Journal Articles

ASBMR: Osteoporosis Screening Interval Assessed

Last Updated: October 18, 2010.

 

Bone mineral density key determinant of screening interval in postmenopausal women

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Baseline bone mineral density appears to be the most important determinant of the osteoporosis screening interval among postmenopausal women, according a study presented at the annual meeting of the American Society for Bone and Mineral Research, held from Oct. 15 to 19 in Toronto.

MONDAY, Oct. 18 (HealthDay News) -- Baseline bone mineral density (BMD) appears to be the most important determinant of the osteoporosis screening interval among postmenopausal women, according a study presented at the annual meeting of the American Society for Bone and Mineral Research, held from Oct. 15 to 19 in Toronto.

As part of the Study of Osteoporotic Fractures, Margaret L. Gourlay, M.D., of the University of North Carolina in Chapel Hill, and colleagues evaluated data on 5,035 women, aged 67 years and older, enrolled in the study between 1986 and 1988, to determine an optimal BMD testing interval according to baseline T-score category over a total of 15 years of prospective follow-up. Women with osteoporosis were excluded from the analysis and the rest of the women were categorized into high-, moderate-, and low-risk groups according to their baseline BMD T-scores at the hip.

The investigators defined the optimal dual energy X-ray absorptiometry (DXA) testing interval as the estimated time during which 10 percent of women with normal BMD or osteopenia became osteoporotic. Adjusting for covariates, the investigators found that the estimated time was 1.26 years for the high-risk group, 5.06 years for the moderate-risk group, and 16.1 years for the low-risk group.

"These results suggest that baseline BMD is the most important determinant of a screening interval, and that an interval of one year should be considered for older postmenopausal women with a T-score ≤−2. An interval of up to five years may be reasonable for osteopenia with T-score above −2," the authors write. "For women with normal BMD, repeat DXA before 10 years is unlikely to be informative."

More Information

Copyright © 2010 HealthDay. All rights reserved.


Previous: AAO: PM Blood Pressure Tied to Glaucoma in Migraineurs Next: Baraclude Sanctioned for Severe Liver Disease

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.